Skip to main content
    E

    Entera Bio Ltd (ENTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.00
    -0.02 (-0.66%)

    Market Cap: $525.90M

    Last updated: Nov 17, 2026 at 4:26 PM ET

    Entera Bio Ltd (ENTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Entera Bio (ENTX) has a market cap of $525.90M and an enterprise value of $260.39M. Its share count is up 208.08% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 50.49% below the market cap, as cash exceeds debt.

    Market Cap$525.90M
    Enterprise Value$260.39M
    Latest price (Nov 17, 2026)$3.00

    Key Dates

    The next earnings report is expected on Mar 25, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 25, 2027 (expected)
    Last Earnings DateNov 6, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 187.56% in the quarter ended Sep 30, 2026 and grew 96.31% a year over 2 years.

    Shares Outstanding145.08M
    Shares Change (YoY)+208.08%
    Shares Change (QoQ)+187.56%
    Share Count Growth (2Y CAGR)+96.31%

    Price Statistics

    The stock is up 10.70% over 52 weeks and trades 3.45% above its 50-day average.

    Beta (1Y)0.86
    52-Week Change+10.70%
    1-Month Change+2.04%
    3-Month Change-3.54%
    6-Month Change+136.22%
    5-Year Change-24.88%
    Total Return (1Y)+10.70%
    Total Return (5Y CAGR)-2.59%
    Return vs SPY (1Y)+3.83%
    Max Drawdown (1Y)-62.69%
    Max Drawdown (3Y)-68.15%
    Sharpe Ratio (1Y)0.13
    Correlation with SPY (1Y)0.11
    50-Day Average$2.90
    200-Day Average$2.00
    52-Week Range$0.91 to $4.20
    RSI (14 Days)48.7
    Average Volume (20 Days)262.69K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 128.41x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio128.41x
    Quick Ratio128.41x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on invested capital is -8.46% over the last 12 months, against a 5-year average of -66.97%.

    Return on Equity (ROE)-10.73%
    Return on Assets (ROA)-10.62%
    Return on Invested Capital (ROIC)-8.46%
    Return on Capital Employed (ROCE)-10.71%
    ROE (5Y Average)-91.24%
    ROA (5Y Average)-79.03%
    ROIC (5Y Average)-66.97%

    Scores

    ENTX has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$7.00K
    Operating Income-$18.41M
    Pretax Income-$29.43M
    Net Income-$29.43M
    EBIT-$29.43M
    Reported EPS (TTM)-$0.38

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 99.00% of the $277.04M in total assets.

    Cash and Equivalents$265.88M
    Total Debt$378.00K
    Net Cash$265.50M
    Net Cash Per Share$1.83
    Working Capital$274.31M
    Shareholder Equity$274.28M
    Book Value Per Share$1.89
    Total Assets$277.04M
    Total Liabilities$2.76M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $51.00K of capital spending, operating cash flow left -$15.84M of free cash flow.

    Operating Cash Flow-$15.79M
    Capital Expenditures$51.00K
    Free Cash Flow-$15.84M
    FCF Per Share-$0.09
    Depreciation and Amortization$32.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Revenue fell 32.07% a year over 3 years.

    Revenue Growth (3Y CAGR)-32.07%
    Revenue Growth (5Y CAGR)-35.11%
    Book Value Per Share Growth (2Y CAGR)-9.93%
    Tangible Book Per Share Growth (2Y CAGR)-9.93%

    Revenue and profit by year

    Dividends and Yields

    ENTX does not pay a dividend. Its free cash flow yield is -3.64%.

    FCF Yield-3.64%
    Buyback Yield3.28%
    Shareholder Yield3.28%

    Peer Position

    Against 5 similar companies, ENTX has the 2nd highest ROIC.

    ROIC-8.46% vs -53.81% median
    Revenue Growth (Trailing 4 Quarters, YoY)-100.00% vs -1.95% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About ENTX

    What is ENTX's market cap?

    Entera Bio has a market cap of $525.90M. Its enterprise value, which adds debt and subtracts cash, is $260.39M.

    How many shares of ENTX are outstanding?

    Entera Bio has 145.08M shares outstanding. The count is up 208.08% from a year earlier.

    Does ENTX pay a dividend?

    No. Entera Bio does not pay a dividend.

    How much debt does ENTX have?

    Entera Bio has $378.00K of total debt and $265.88M of cash and equivalents, a net cash position of $265.50M.